| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_116c851e729089df9a427027272fa290 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-66
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-71
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-94
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-524 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-241
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-00 |
| filingDate |
2021-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b92c3d55c976d195416c75d362de3ec1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e6fc831bc4b0c2d316fc238d4bdc8403
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_de39f22a088830401af967d2caa76bc4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_36a4b7cb61a6d52bb49f9e5e49889b17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_57cc72ea3d18097fbd6a8b06b2a75ec6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9afb7a98b456c5053d661a71715720b8 |
| publicationDate |
2022-06-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2022136238-A1 |
| titleOfInvention |
Effectorless fc molecules |
| abstract |
The present invention provides molecules comprising a modified Fc region which do not mediate antibody effector functions such as antibody-dependent cellular cytotoxicity (ADCC) but maintain a long serum half-life due to binding to the neonetal Fc receptor (FcRn). To this end, the molecules of the present invention do not comprise the disulfide bridges of the antibody hinge region but are linked C-terminally by at least two covalent bonds. Furthermore, the molecules of the present invention comprise CH2 domains with an additional disulfide bond. |
| priorityDate |
2020-12-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |